Organon & Co. Common Stock vs Stanley Black & Decker, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Stanley Black & Decker, Inc. trades at $90.33 (market cap $13.64B). The key difference: Stanley Black & Decker, Inc. is far larger — about 3.8× Organon & Co. Common Stock's market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| OGN | SWK | |
|---|---|---|
Market Cap | $3.61B | $13.64B |
Volume | 1,808,049 | 1,097,590 |
Sector | Health | Industrials |
52-Week High | $13.81 | $104.00 |
52-Week Low | $5.70 | $62.12 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.03B | $17.80B |
Dividend Yield | 0.58% | 3.72% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Stanley Black & Decker (SWK) trades at $90.71, up 2.32% today, with a bearish technical outlook but improving fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue remains stable around $15.1B, while net income margin improved to 2.65% in 2025. Valuation ratios show a P/E of 22.18 and P/S of 0.9, indicating reasonable pricing relative to sales. Recent news highlights product launches and dividend payments, with the company focusing on margin gains and brand strength.
SWK presents a mixed outlook: analyst consensus is cautious with a $93 price target, but fundamentals are strengthening with projected 2026 net income growth. Key risks include competitive pressures and macroeconomic headwinds, while opportunities lie in operational execution and market share gains. The stock's current level near consensus target suggests limited upside unless earnings surprises materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →